Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VRK1 | Q99986 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 8/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 8/20 | 0.38 |
| ▸ | CACNA1I | Q9P0X4 | 8/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.35 |
| ▸ | PLK1 | P53350 | 1/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PREP | P48147 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4076168 | 0.81 | RPS6KA3 (0.42) | VRK1BRD4PLK1 | |
| SCHEMBL4079498 | 0.81 | MAPT (0.39) | VRK1BRD4PLK1HPGD | |
| SCHEMBL4080835 | 0.81 | PIP4K2A (0.39) | PLK1 | |
| SCHEMBL4089766 | 0.81 | VRK1 (0.39) | VRK1 | |
| SCHEMBL1203702 | 0.79 | POLB (0.41) | MAPK1TSHR | |
| SCHEMBL2397767 | 0.77 | GAA (0.36) | VRK1CACNA1GCACNA1HCACNA1IMAPK1 | |
| SCHEMBL4080829 | 0.77 | ALOX12 (0.43) | ALOX12CACNA1GCACNA1HCACNA1IBRD4 | |
| SCHEMBL4082908 | 0.73 | PIP4K2A (0.36) | BRD4PLK1 | |
| SCHEMBL1203549 | 0.73 | PIP4K2A (0.38) | BRD4PLK1 | |
| SCHEMBL16390761 | 0.72 | PLK2 (0.44) | VRK1BRD4PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517873-B2 | Substituted pyrimidodiazepines | HOFFMAN-LA ROCHE INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20080234255-A1 | SUBSTITUTED PYRIMIDODIAZEPINES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234255-A1 | SUBSTITUTED PYRIMIDODIAZEPINES | PLK1, CCNI, CDK1 | VRK1 1326/4885ALOX12 3321/4885CACNA1G 3751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.